Zentalis selects 400mg QD 5:2 azenosertib monotherapy as pivotal dose for Cyclin E1-positive ovarian cancer

Zentalis Pharmaceuticals, Inc.

Pre-specified interim analysis from DENALI Part 2a showed clearly differentiated response rate at 400mg QD 5:2 over 300mg QD 5:2 and comparable safety profiles.
New DENALI Part 2c cohort to include ~40 patients previously treated with taxane-containing regimen for PROC, enrollment expected Q2 2026.
Company expects to complete enrollment in all DENALI Part 2 cohorts and provide topline readout by year-end 2026.
Azenosertib therapeutic profile supports advancement into confirmatory ASPENOVA Phase 3 trial and pre-commercial activities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.